Trial Profile
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2023
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary) ; Antipsychotics; Risperidone; Risperidone
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms Route 6
- Sponsors Janssen Research & Development; Janssen-Cilag
- 25 Aug 2023 Results of subgroup analysis (n=90 from Asia region ;India, Taiwan, Malaysia, Hong Kong, and Korea) assessing efficacy and safety of paliperidone palmitate 6-monthly (PP6M) for patients with schizophrenia published in the Medicine
- 09 Nov 2022 Results assessing patient satisfaction with treatment and their social roles with 6-monthly paliperidone palmitate (PP) formulation (PP6M) and 3-monthly formulation in adult patients with schizophrenia, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 18 Oct 2022 Results of post-hoc sub-group analysis efficacy and safety of paliperidone palmitate 6-month versus paliperidone palmitate 3-month, presented at the 35th Annual Congress of the European College of Neuropsychopharmacology.